Skip to main content

Our clinically available, laboratory-developed test

ArteraAI offers AI-enabled predictive and prognostic cancer tests, including the first of its kind for patients with localized prostate cancer.


View a Sample Test Report

Explore the ArteraAI Prostate Test report and how it can help personalize prostate cancer treatment.

The science behind the ArteraAI Prostate Test

ArteraAI’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient’s clinical data. The AI combines this information to predict whether a patient will benefit from hormone therapy and estimate long-term outcomes.

The algorithm has been developed using large sets of data, from thousands of patients and tens of thousands of pathology slide images, and has been clinically validated with multiple Phase 3 randomized trials.

Predicting therapeutic benefit from hormone therapy

Our predictive biomarker has the potential to guide the use of short-term androgen deprivation therapy (ST-ADT) in men with localized prostate cancer.Spratt DE, et al. 2022 ASCO GU Cancers Symposium. Abstract 223

Current method

Today’s standard of care for men with intermediate localized prostate cancer is to treat them with short-term androgen-deprivation therapy in combination with radiation therapy (RT + ST-ADT), but only 34% actually need it. Side effects include medical castration.

Overall Analysis Population (RTOG 9408)

Shows marginal benefit to including short-term hormone therapy in combination with radiation therapy.

Hazard ratio: 0.64 (95% CI, 0.45-0.90, P = 0.01)
n = 1719 patients studied

With ArteraAI Prostate Test

The AI identifies the 34% of patients who may greatly benefit from short-term hormone therapy.

AI Biomarker Negative

Identify patients who may not need short-term
hormone therapy.

Hazard ratio: 0.92 (95% CI, 0.59-1.43, P = 0.71)
n = 1046 patients studied

Interaction p-value = 0.002

AI Biomarker Positive

Identify patients who may greatly benefit from short-term
hormone therapy.

Hazard ratio: 0.34 (95% CI, 0.19-0.63, P < 0.001)
n = 673 patients studied

Interaction p-value = 0.002

Outperforming standard clinical tools

First and only AI-derived prognostic biomarker test to be recommended as a risk stratification tool in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®️) for Prostate Cancer.Esteva A, et al. Nature Digital Medicine. 2022;5(1):71; Esteva A, et al. 2022 ASCO GU Cancers Symposium. Abstract 222; NCCN, National Comprehensive Cancer Network.

The test uses AI models to estimate long-term, clinically relevant outcomes for:

  • Distant metastasis (DM)
  • Biochemical failure (BF)
  • Prostate cancer-specific survival (PCSS)
  • Overall survival (OS)

Distant metastasis (DM)

Refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes.

(p <0.001*)
(p <0.001*)

Biochemical failure (BF)

Defined as any increase of at least 2 ng/mL from the lowest PSA reading.

(p <0.001*)
(p <0.004*)

Prostate cancer-specific survival (PCSS)

Defined from the time of recurrence until death from disease.

(p <0.001*)

Overall survival (OS)

A way to measure how well a new treatment works by reviewing a patient’s lifespan. This can begin at the date of diagnosis or start of treatment.

(p <0.001*)

ArteraAI benefits both clinicians and patients


First-ever predictive and prognostic test

ArteraAI Prostate Test is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer.


Robust model validation

Multiple Phase 3 randomized trials with up to 15-year follow-up were used to develop and validate prognostic and predictive AI models.


Representing diverse populations

African American men are disproportionately affected, making up 16.3% of prostate cancer patients. ArteraAI’s models were developed using clinical trial data comprising approximately 20% African American men.Roach et al. 2022. Prostate cancer risk in African American men evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology phase III clinical trials. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 108-108.

Ordering is easy with ArteraAI

The ArteraAI Prostate Test is a laboratory developed testTesting is performed by ArteraAI, located at 6800 Southpoint Pkwy Suite 950, Jacksonville, Florida 32216. The ArteraAI Prostate Test was developed and its performance characteristics were determined by ArteraAI. This Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) as qualified to perform high-complexity clinical laboratory testing. This test is used for clinical purposes and should not be regarded as investigational or for research. This test has not been cleared or approved by the U.S. Food and Drug Administration. that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL.

The ArteraAI Prostate Test is intended to help clinicians determine the therapeutic benefit for patients who have been diagnosed with localized prostate cancer who have not yet received androgen deprivation therapy.

Yes! You can visit the ArteraAI Test Report page to explore each section of the report to better understand the results.

Currently, the ArteraAI Prostate Test may be ordered in 48 states. ArteraAI is currently not accepting orders from California or New York. ArteraAI is actively pursuing licensing in these states and will post future updates to certification status on this website.

After you reach out to us, a member of our Customer Success team will set up an account in the ArteraAI Portal to enable order submission.

No. Ordering of the ArteraAI Prostate Test is limited to clinicians whose license and scope of practice allows them to order the test. However, we encourage patients to share information about ArteraAI with their doctor.

Using the ArteraAI Prostate Test, results can be shared within 2-3 days after receipt of the patient’s specimen.

The out-of-pocket cost for the ArteraAI Prostate Test will be based on the patient’s insurance plan. If the patient is covered by Medicare Plan B, they should have zero out-of-pocket costs for the ArteraAI Prostate Test. If the patient is covered by private insurance, financial liability will be subject to the terms of their plan taking into consideration copays, coinsurance and deductibles. Patients should contact for additional questions about their estimated out-of-pocket liability for the test.

Meet the collaborators who make our work possible

Left Icon

Order the ArteraAI
Prostate Test for
your patient.

Start your order
Right Icon

Be your own advocate!
Share this information
with your doctor today.

Send to doctor